Artiva Biotherapeutics (ARTV)

• Market cap: $225M
• 1 day: -15.35%
• 5 days: -27.2%
• 1 month: 66.97%
• 3 months: 103.58%
• 6 months: 92.39%
• Year to date: 115.13%
• 1 year: 271.43%
• 5 years: -24.17%
• 10 years: -24.17%
• Sector: Healthcare
• Industry: Biotechnology

About: Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).

Employees: 104